Loading…
Syrhatech, a CDMO specializing in injectable medical devices based on hyaluronic acid, has closed an investment of CHF 4.5 million from strategic investors. The funds will be used to strengthen its R&D team in Geneva and deploy new production capacity at its plant in Chambéry, France.
| Site | Largest | Latest |
|---|---|---|
| Chambéry, France | $5.00M | 2025-04-01 |